WO2023027674A2 - Production of hydrogels and bioscaffolds originated from decellularized brain/spinal meninx for regenerative and reconstructive medical applications - Google Patents
Production of hydrogels and bioscaffolds originated from decellularized brain/spinal meninx for regenerative and reconstructive medical applications Download PDFInfo
- Publication number
- WO2023027674A2 WO2023027674A2 PCT/TR2022/050899 TR2022050899W WO2023027674A2 WO 2023027674 A2 WO2023027674 A2 WO 2023027674A2 TR 2022050899 W TR2022050899 W TR 2022050899W WO 2023027674 A2 WO2023027674 A2 WO 2023027674A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bioscaffolds
- hydrogels
- decellularized
- production
- growth factor
- Prior art date
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 33
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 20
- 210000004556 brain Anatomy 0.000 title claims abstract description 13
- 230000001172 regenerating effect Effects 0.000 title claims abstract description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 17
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 17
- 210000002744 extracellular matrix Anatomy 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 4
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 210000001808 exosome Anatomy 0.000 claims description 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 229920005615 natural polymer Polymers 0.000 claims description 3
- 229920001059 synthetic polymer Polymers 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 102000019034 Chemokines Human genes 0.000 claims description 2
- 108010012236 Chemokines Proteins 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920000715 Mucilage Polymers 0.000 claims description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 235000013311 vegetables Nutrition 0.000 claims description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 7
- 108010082117 matrigel Proteins 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000003973 irrigation Methods 0.000 description 4
- 230000002262 irrigation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000005202 decontamination Methods 0.000 description 3
- 230000003588 decontaminative effect Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 210000000576 arachnoid Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003446 pia mater Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3633—Extracellular matrix [ECM]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Definitions
- the invention relates to the production of hydrogels and bioscaffolds that originate from decellularized brain/spinal meninx for regenerative and reconstructive medical applications that can be used in humans and animals and that are obtained from healthy human and/or animal tissue.
- Matrigel® A mouse tumor matrix (Engelbreth-Holm- Swarm (EHS) mouse sarcoma cells) extract called Matrigel® provides copious amounts of basal membrane protein sources such as laminin, collagen IV, heparan sulfate, etc. Matrigel® has a structure similar to the original matrix and gelates at room temperature. Embryonic tissue explants, stem cells, and various cell types differentiate when cultured in Matrigel®. Matrigel® is used in angiogenesis, cell proliferation, spheroid formation, organoid formation from a single cell, etc. in various in vitro studies.
- EHS Engelbreth-Holm- Swarm
- Matrigel® due to its murine origins and potential tumorigenicity, Matrigel® cannot be used in humans.
- its content is not well defined, the role of its components in biological activities is unknown, it is expensive, its content varies based on the production method, and its storage time is short.
- the object of the present invention is to provide the production of hydrogels and bioscaffolds that originate from decellularized brain/spinal meninx that can be used in humans and animals and that are obtained from healthy human and/or animal tissue.
- Another object of the present invention is to provide the production of hydrogels and bioscaffolds that can be easily obtained, that are inexpensive, and that have a longer storage time.
- Figure 1 The view of the production diagram of the hydrogels and bioscaffolds of the invention.
- the subject of the invention is the production of decellularized hydrogels and bioscaffolds for regenerative and reconstructive medical applications; and comprises the steps of basically accelerating tissue regeneration, differentiating the stem/progenitor cells, triggering angiogenesis and obtaining extracellular matrix (ECM) hydrogels and bioscaffolds by treating the brain or spinal meninx tissue which are the support material for stems/cells with decellularization technique.
- ECM extracellular matrix
- the subject of the invention is the production of decellularized hydrogels and bioscaffolds obtained from the brain or spinal meninx and may comprise one of the steps of;
- ECM hydrogels and bioscaffolds by themselves and/or with natural polymers such as vegetable mucilage, cellulose, alginate, chitosan, fibrin, elastin, collagen (of vertebrate and/or invertebrate origin), gelatin, decellularized matrices,
- ECM hydrogels and bioscaffolds by themselves and/or with synthetic polymers such as polylactic acid (PLA), polyglycolic acid (PGA), polyglycolic-co-lactic acid (PLGA), poly-e-caprolactone (PCL), etc.
- synthetic polymers such as polylactic acid (PLA), polyglycolic acid (PGA), polyglycolic-co-lactic acid (PLGA), poly-e-caprolactone (PCL), etc.
- ECM hydrogels and bioscaffolds with growth factors such as epidermal growth factor (EGF), nerve growth factor (NGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), Brain-derived neurotrophic factor (BDNF), transforming growth factor a (TGF-a), transforming growth factor P (TGF- P), and vascular endothelial growth factor (VEGF), etc.
- growth factors such as epidermal growth factor (EGF), nerve growth factor (NGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), Brain-derived neurotrophic factor (BDNF), transforming growth factor a (TGF-a), transforming growth factor P (TGF- P), and vascular endothelial growth factor (VEGF), etc.
- growth factors such as epidermal growth factor (EGF), nerve growth factor (NGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), Brain-derived neurotrophic factor (BDNF), transforming growth factor a (TGF
- the brain/spinal meninx as the subject of the invention is composed of three membranes (dura mater, arachnoid and pia mater) responsible for the protection of the brain and the spine.
- the Dura mater is the outermost membrane that surrounds the other meninx.
- the middle layer is the arachnoid and the innermost layer is the pia mater.
- the role of the meninx is to protect the central nervous system together with the cerebrospinal fluid. Apart from its protective function, the meninx regulates the pathological and physiological events of the central nervous system. Meninx contributes to neuro-homeostasis by secreting many trophic factors in adults.
- the micro-architecture of the meninx contains a laminin-rich extracellular matrix that secretes growth factors that have the potential to modulate stem cell homeostasis and cortical function.
- the extracellular matrix of the meninx contains large amounts of collagen types I, III, and IV, as well as non-collagenous proteins such as tenascin and fibronectin.
- the extracellular matrix of the meninx contains basic fibroblast growth factor, insulin-like growth factor-II, stromal cell-derived factor I, retinoic acid and heparan sulfate.
- the said material can be obtained from slaughterhouses.
- the meninx (1) is first separated from the brain or the spinal cord obtained from the slaughterhouse or cadaver mechanically (2). After that, unwanted tissues such as fat, etc. are removed from the meninx (3) and irrigated thoroughly (4) to dispose of blood, etc. residues.
- the meninx is divided into approximately 2 centimetres (cm) x 2 cm pieces.
- the decellularization can be performed chemically or with supercritical carbon dioxide (CO2) /ethanol. In the said technique, the decellularization treatment is performed by means of chemical methods.
- the meninx is first treated for 24 hours with hypotonic 10 millimolar (mM) Trizma hydrochloride and 5 mM EDTA solution (pH 8.0) (5).
- the meninx is irrigated with ultra pure water for 24 hours (4) after the hypotonic solution.
- the materials are treated in a magnetic agitator for 48 hours with hypotonic 50 mM Trizma hydrochloride, 5 mM EDTA solution (pH 8.0) comprising 1% Triton X-100 (v/v) detergent (6).
- the meninx is washed 24 hours with ultra pure water (4) in order to remove the detergent residue.
- the materials are incubated at 37.5 °C for 24 hours with Deoxyribonuclease (DNase) (200 micrograms/milliliter (pg/mL)) and Ribonuclease (RNase) (50 pg/mL) solutions prepared in 10 mM magnesium chloride (MgCl) and 50 mM Trizma (pH: 7.5) buffer (7).
- DNase Deoxyribonuclease
- RNase Ribonuclease
- the scaffolds are left for agitation to be washed for 24 hours with pure water (4).
- the decellularized meninx which is purified from chemical residues by irrigation (9) is placed in a tube containing 20 mL of ultra pure water for 5 g of wet tissue and homogenized for 10 minutes with a cool pack to prevent the temperature from rising too much (10).
- the homogenized solution is molded (11) and left overnight at -26°C to be readied for freeze- drying. Prepared materials are freeze-dried for 24 hours (12).
- the freeze-dried meninges are taken from the petri dish and ground into a powder with the help of a grinder (13).
- Centrifugation is performed at 14,000 rpm for 5 minutes to remove undigested particles from the pre-gel (the gel that has not been neutralized as a result of digestion) (15).
- the pre-gel is drawn carefully with the help of a micropipette and taken into a vial.
- the vial is left at +4°C until it is used (the pre-gel rests at +4°C for at least 1 day before it is neutralized).
- the hydrogel and bioscaffold of the invention are obtained from healthy tissue and are also treated with many chemicals and enzymes during decellularization. In the final step, it is treated with the enzyme pepsin to obtain a gel. All of these steps minimize the nuclear materials (DNA and RNA) at the origin of the material that causes tissue rejection and/or host response. Therefore, the hydrogel and bioscaffold of the invention can be used in humans. Its content was determined by proteomic analysis. Since Matrigel® is of tumorigenic origin, its content varies from production to production. Since the invention is obtained from healthy tissue, its content does not change based on the production. It is cheaper because it can be obtained easily. The analyses revealed that the storage time of the invention is much longer than that of Matrigel®.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
The invention relates to the production of hydrogels and bioscaffolds that originate from decellularized brain/ spinal meninx for regenerative and reconstructive medical applications that can be used in humans and that are obtained from healthy tissue.
Description
PRODUCTION OF HYDROGELS AND BIOSCAFFOLDS ORIGINATED FROM DECELLULARIZED BRAIN/SPINAL MENINX FOR REGENERATIVE AND RECONSTRUCTIVE MEDICAL APPLICATIONS
Technical Field
The invention relates to the production of hydrogels and bioscaffolds that originate from decellularized brain/spinal meninx for regenerative and reconstructive medical applications that can be used in humans and animals and that are obtained from healthy human and/or animal tissue.
Prior Art
A mouse tumor matrix (Engelbreth-Holm- Swarm (EHS) mouse sarcoma cells) extract called Matrigel® provides copious amounts of basal membrane protein sources such as laminin, collagen IV, heparan sulfate, etc. Matrigel® has a structure similar to the original matrix and gelates at room temperature. Embryonic tissue explants, stem cells, and various cell types differentiate when cultured in Matrigel®. Matrigel® is used in angiogenesis, cell proliferation, spheroid formation, organoid formation from a single cell, etc. in various in vitro studies.
However, due to its murine origins and potential tumorigenicity, Matrigel® cannot be used in humans. In addition, its content is not well defined, the role of its components in biological activities is unknown, it is expensive, its content varies based on the production method, and its storage time is short.
Various improvements have been made in the art for the fabrication of hydrogels and bioscaffolds.
In the patent document numbered KR20170003916A in the state of the art, methods for preparing sterilized, gelated, solubilized extracellular matrix (ECM) compositions beneficial as cell growth matrices are mentioned.
In the patent document numbered JP2019513125A in the state of the art, a composition comprising nanovesicles derived from isolated extracellular matrix and a pharmaceutically acceptable carrier is described. Methods that generate ECM-derived nanovesicles are also described.
When the hydrogels and bioscaffolds present in the art were examined, a need for developing a hydrogel and bioscaffold obtained by using brain/spinal meninx emerged.
The object of the Invention
The object of the present invention is to provide the production of hydrogels and bioscaffolds that originate from decellularized brain/spinal meninx that can be used in humans and animals and that are obtained from healthy human and/or animal tissue.
Another object of the present invention is to provide the production of hydrogels and bioscaffolds that can be easily obtained, that are inexpensive, and that have a longer storage time.
Detailed Description of the Invention
The hydrogel and bioscaffold realized to achieve the purposes of the present invention are shown in the attached figure.
In this figure;
Figure 1: The view of the production diagram of the hydrogels and bioscaffolds of the invention.
The steps in the figure have been numbered individually, and the corresponding descriptions are given below.
1. Brain or spinal meninx
2. Mechanical separation
3. Removing unwanted tissue such as fat, etc. from the meninx
4. Irrigation
5. Treating with hypotonic Trizma hydrochloride and Ethylenediamine tetraacetic acid (EDTA) solution
6. Treating in the agitator
7. Incubating at 37.5° C for 24 hours with the solutions
8. Decontamination
9. Obtaining decellularized meninx purged from chemical residues by means of irrigation
10. Homogenization of the decellularized meninx
11. Moulding of the homogenized solution
12. Freeze drying
13. Pulverizing with a grinder
14. Leaving for digestion for 72 hours in the magnetic stirrer
15. Centrifuging
16. Neutralizing
17. Incubating
18. MeninGEL Hydrogel
19. MeninRIX bioscaffold
The subject of the invention is the production of decellularized hydrogels and bioscaffolds for regenerative and reconstructive medical applications; and comprises the steps of basically accelerating tissue regeneration, differentiating the stem/progenitor cells, triggering angiogenesis and obtaining extracellular matrix (ECM) hydrogels and bioscaffolds by treating the brain or spinal meninx tissue which are the support material for stems/cells with decellularization technique.
The subject of the invention is the production of decellularized hydrogels and bioscaffolds obtained from the brain or spinal meninx and may comprise one of the steps of;
Combining the obtained ECM hydrogels and bioscaffolds by themselves and/or with natural polymers such as vegetable mucilage, cellulose, alginate, chitosan, fibrin, elastin, collagen (of vertebrate and/or invertebrate origin), gelatin, decellularized matrices,
Combining the obtained ECM hydrogels and bioscaffolds by themselves and/or with
synthetic polymers such as polylactic acid (PLA), polyglycolic acid (PGA), polyglycolic-co-lactic acid (PLGA), poly-e-caprolactone (PCL), etc.,
Combining the obtained ECM hydrogels and bioscaffolds with growth factors such as epidermal growth factor (EGF), nerve growth factor (NGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), Brain-derived neurotrophic factor (BDNF), transforming growth factor a (TGF-a), transforming growth factor P (TGF- P), and vascular endothelial growth factor (VEGF), etc.,
Combining the obtained ECM hydrogels and bioscaffolds with exosomes obtained from stem/cell and/or bodily fluids of human and/or animal origin,
Combining the obtained ECM hydrogels and bioscaffolds with cytokines, chemokines and/or hormones.
The brain/spinal meninx as the subject of the invention is composed of three membranes (dura mater, arachnoid and pia mater) responsible for the protection of the brain and the spine. The Dura mater is the outermost membrane that surrounds the other meninx. The middle layer is the arachnoid and the innermost layer is the pia mater. The role of the meninx is to protect the central nervous system together with the cerebrospinal fluid. Apart from its protective function, the meninx regulates the pathological and physiological events of the central nervous system. Meninx contributes to neuro-homeostasis by secreting many trophic factors in adults. If the micro-architecture of the meninx is examined, it is found that it contains a laminin-rich extracellular matrix that secretes growth factors that have the potential to modulate stem cell homeostasis and cortical function. Moreover, the extracellular matrix of the meninx contains large amounts of collagen types I, III, and IV, as well as non-collagenous proteins such as tenascin and fibronectin. In addition, the extracellular matrix of the meninx contains basic fibroblast growth factor, insulin-like growth factor-II, stromal cell-derived factor I, retinoic acid and heparan sulfate.
The said material can be obtained from slaughterhouses. The meninx (1) is first separated from the brain or the spinal cord obtained from the slaughterhouse or cadaver mechanically (2). After that, unwanted tissues such as fat, etc. are removed from the meninx (3) and irrigated thoroughly (4) to dispose of blood, etc. residues. To make the decellularization easier, the meninx is divided into approximately 2 centimetres (cm) x 2 cm pieces. The decellularization can be performed chemically or with supercritical carbon dioxide (CO2) /ethanol. In the said technique, the decellularization treatment is performed by means of
chemical methods. The meninx is first treated for 24 hours with hypotonic 10 millimolar (mM) Trizma hydrochloride and 5 mM EDTA solution (pH 8.0) (5). The meninx is irrigated with ultra pure water for 24 hours (4) after the hypotonic solution. Then, the materials are treated in a magnetic agitator for 48 hours with hypotonic 50 mM Trizma hydrochloride, 5 mM EDTA solution (pH 8.0) comprising 1% Triton X-100 (v/v) detergent (6). In the remainder of this procedure, the meninx is washed 24 hours with ultra pure water (4) in order to remove the detergent residue. Then, the materials are incubated at 37.5 °C for 24 hours with Deoxyribonuclease (DNase) (200 micrograms/milliliter (pg/mL)) and Ribonuclease (RNase) (50 pg/mL) solutions prepared in 10 mM magnesium chloride (MgCl) and 50 mM Trizma (pH: 7.5) buffer (7). The meninx is irrigated with ultra pure water several times at the end of this period (4). After the irrigation, decontamination is performed within a solution containing 4% ethanol (v/) and 0.1% peracidic acid (v/v) for 5 hours (8). Following decontamination, the scaffolds are left for agitation to be washed for 24 hours with pure water (4). The decellularized meninx which is purified from chemical residues by irrigation (9) is placed in a tube containing 20 mL of ultra pure water for 5 g of wet tissue and homogenized for 10 minutes with a cool pack to prevent the temperature from rising too much (10). The homogenized solution is molded (11) and left overnight at -26°C to be readied for freeze- drying. Prepared materials are freeze-dried for 24 hours (12). The freeze-dried meninges are taken from the petri dish and ground into a powder with the help of a grinder (13). Then, 20mM acetic acid, 1 mg/ml pepsin solution is prepared and mixed at a low speed on a magnetic stirrer. Finally, 10 mg/ml of decellularized meninx are added to the solution and allowed to digest for 72 hours in a magnetic stirrer (14).
Centrifugation is performed at 14,000 rpm for 5 minutes to remove undigested particles from the pre-gel (the gel that has not been neutralized as a result of digestion) (15). The pre-gel is drawn carefully with the help of a micropipette and taken into a vial. The vial is left at +4°C until it is used (the pre-gel rests at +4°C for at least 1 day before it is neutralized).
For neutralization, 10 pl of 7.5% sodium bicarbonate (NaHCO3) is added to each 100 pl of pre-gel and neutralized with a micropipette at +4°C (on a cool pack) (16).
Neutralized gels are incubated at 37°C for 1 hour (17) to obtain MeninGEL Hydrogel (18).
If the MeninGEL hydrogel is freeze-dried for one night (12), the MeninRIX bioscaffold is
obtained (19).
Said hydrogel is called MeninGEL and the bioscaffold is called MeninRIX bioscaffold. The hydrogel and bioscaffold of the invention are obtained from healthy tissue and are also treated with many chemicals and enzymes during decellularization. In the final step, it is treated with the enzyme pepsin to obtain a gel. All of these steps minimize the nuclear materials (DNA and RNA) at the origin of the material that causes tissue rejection and/or host response. Therefore, the hydrogel and bioscaffold of the invention can be used in humans. Its content was determined by proteomic analysis. Since Matrigel® is of tumorigenic origin, its content varies from production to production. Since the invention is obtained from healthy tissue, its content does not change based on the production. It is cheaper because it can be obtained easily. The analyses revealed that the storage time of the invention is much longer than that of Matrigel®.
Claims
1. The production of decellularized hydrogels and bioscaffolds for regenerative and reconstructive medical applications; comprising the step of accelerating tissue regeneration, differentiating the stem/progenitor cells, triggering angiogenesis and obtaining extracellular matrix (ECM) hydrogels and bioscaffolds by treating the brain or spinal meninx tissue which are the support material for stems/ cells obtained from humans and/or animals with decellularization technique.
2. The production of decellularized hydrogels and bioscaffolds according to Claim 1, characterized in that the obtained ECM hydrogels and bioscaffolds are combined by themselves and/or with natural polymers, synthetic polymers, growth factors, exosomes, cytokines, chemokines, and/or hormones.
3. The production of decellularized hydrogels and bioscaffolds according to Claim 2, characterized in that the natural polymers are vegetable mucilage, cellulose, alginate, chitosan, fibrin, elastin, collagen (of vertebrate and/or invertebrate origin), gelatin, and decellularized matrices.
4. The production of decellularized hydrogels and bioscaffolds according to Claim 2, characterized in that the synthetic polymers are polylactic acid (PLA), polyglycolic acid (PGA), polyglycolic-co-lactic acid (PLGA), and poly-e-caprolactone (PCL).
5. The production of decellularized hydrogels and bioscaffolds according to Claim 2, characterized in that the growth factors are epidermal growth factor (EGF), nerve growth factor (NGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), Brain-derived neurotrophic factor (BDNF), transforming growth factor a (TGF-a), transforming growth factor P (TGF-P), and vascular endothelial growth factor (VEGF).
6. The production of decellularized hydrogels and bioscaffolds according to Claim 2, characterized in that the exosomes are exosomes obtained from stem/cell and/or bodily fluids of human and/or animal origin.
7
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TR2021/013582 | 2021-08-27 | ||
| TR2021/013582A TR2021013582A2 (en) | 2021-08-27 | 2021-08-27 | PRODUCTION OF DECELLULARIZED BRAIN/SPINAL CORD MENINGE-DERIVED HYDROGELS AND BIOSCALES FOR REGENERATIVE AND RECONSTRUCTIVE MEDICINE APPLICATIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2023027674A2 true WO2023027674A2 (en) | 2023-03-02 |
| WO2023027674A3 WO2023027674A3 (en) | 2023-05-04 |
Family
ID=83996042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2022/050899 WO2023027674A2 (en) | 2021-08-27 | 2022-08-24 | Production of hydrogels and bioscaffolds originated from decellularized brain/spinal meninx for regenerative and reconstructive medical applications |
Country Status (2)
| Country | Link |
|---|---|
| TR (1) | TR2021013582A2 (en) |
| WO (1) | WO2023027674A2 (en) |
-
2021
- 2021-08-27 TR TR2021/013582A patent/TR2021013582A2/en unknown
-
2022
- 2022-08-24 WO PCT/TR2022/050899 patent/WO2023027674A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023027674A3 (en) | 2023-05-04 |
| TR2021013582A2 (en) | 2021-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | 3D porous calcium-alginate scaffolds cell culture system improved human osteoblast cell clusters for cell therapy | |
| Fu et al. | Decellularization of porcine skeletal muscle extracellular matrix for the formulation of a matrix hydrogel: a preliminary study | |
| Tian et al. | Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering | |
| JP5483035B2 (en) | Method for producing porous three-dimensional support using animal tissue powder and porous three-dimensional support produced using the same | |
| US9814744B2 (en) | Decellularized adipose cell growth scaffold | |
| CN111905146B (en) | Acellular bone matrix hydrogel retaining natural hydroxyapatite and preparation method thereof | |
| CN104307045B (en) | A kind of preparation method of the Acellular bone membrane material in natural tissues source | |
| Sun et al. | Polylysine-decorated macroporous microcarriers laden with adipose-derived stem cells promote nerve regeneration in vivo | |
| CN112980001B (en) | Collagen composite hyaluronic acid gel, extracellular matrix bionic material and preparation method | |
| Jiang et al. | Decellularized extracellular matrix: a promising strategy for skin repair and regeneration | |
| CN105079783A (en) | Pharmaceutical composition and preparation method and application thereof | |
| Narayan et al. | Ectopic vascularized bone formation by human mesenchymal stem cell microtissues in a biocomposite scaffold | |
| CN1836034A (en) | Methods of producing neurons | |
| CN102861360A (en) | Neural restoration promoting material as well as preparation method and application thereof | |
| Pu et al. | Injectable human decellularized adipose tissue hydrogel containing stem cells enhances wound healing in mouse | |
| US20210322644A1 (en) | Biomaterial comprising adipose-derived stem cells and gelatin and method for producing the same | |
| Apinun et al. | Osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells encapsulated in Thai silk fibroin/collagen hydrogel: a pilot study in vitro | |
| Kuo et al. | Effect of bovine pituitary extract on the formation of neocartilage in chitosan/gelatin scaffolds | |
| CN114686421B (en) | Preparation method and application of lung tissue extracellular matrix-free microcarrier | |
| WO2023027674A2 (en) | Production of hydrogels and bioscaffolds originated from decellularized brain/spinal meninx for regenerative and reconstructive medical applications | |
| ES2684856A2 (en) | Method for producing a decellularized tissue matrix | |
| Iqbal et al. | Tissue engineering and regenerative medicine potentialities of materials-based novel constructs-A review | |
| Yin et al. | Fabrication of blended gelatin–polyvinyl alcohol–chitosan scaffold for wound regeneration | |
| Kumaresan et al. | Development of Human Umbilical cord based scaffold for tissue engineering application | |
| KR20210072266A (en) | Adipose tissue-derived extracellular matrix scaffold and method of making the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase |
Ref country code: DE |